EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study

Aliya A Khan iD, Hajar AbuAlrob, Iman M'Hiri, Dalal S Ali, Karel Dandurand, Hosay Said, Hisham Alkassem, Yasser Hakami, Ismail Hweija, Salman Iqbal, Mihai Romanovschi, Shehryar Mehmood und 5 weitere

Endocrine · 2023

DOI: 10.1007/s12020-022-03230-5 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Endocrine, 2023. Verfasst von Aliya A Khan und 16 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Ontario, Canada. aliya@mcmaster.ca. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Osteoporosis, Fractures, Bone. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We evaluated the effect of low dose denosumab (30 mg every 6 months) on the prevention of bone loss following a switch from standard dose (60 mg of denosumab every 6 months) in a prospective observational study.

Methods

We recruited 114 women 50–90 years of age with postmenopausal osteoporosis at a moderate fracture risk without prior fragility fractures, who had been on denosumab 60 mg every 6 month. These women switched to low dose denosumab 30 mg every 6 months. Mean percentage change in lumbar spine (LS), femoral neck (FN), total hip (TH) and 1/3 distal radius (1/3RAD) BMD at 12 and 24 months were evaluated. Predictors for change in BMD were explored. Subgroup analysis for patients on denosumab 60 mg every 6 months for

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalBone Density Conservation AgentsOsteoporosisFractures, BoneHumansFemaleBone DensityDenosumabPostmenopause

Stichwörter der Autor:innen

Bone mineral densityDenosumabObservational studyPostmenopausal osteoporosis

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • McMaster University, Hamilton, Ontario, Canada. aliya@mcmaster.ca.
  • McMaster University, Hamilton, Ontario, Canada.
  • Bone Research and Education Centre, Oakville, Ontario, Canada.

ORCID-Profile: Aliya A Khan

Zitieren

APA

Khan, A. A., AbuAlrob, H., M'Hiri, I., Ali, D. S., Dandurand, K., Said, H., Alkassem, H., Hakami, Y., Hweija, I., Iqbal, S., Romanovschi, M., Mehmood, S., Zariffeh, H., Guyatt, G., Ibrahim, Q., Brignardello-Petersen, R., & Syed, H. I. (2023). Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine. https://doi.org/10.1007/s12020-022-03230-5

Vancouver

Khan AA, AbuAlrob H, M'Hiri I, Ali DS, Dandurand K, Said H, et al. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine. 2023. doi:10.1007/s12020-022-03230-5

BibTeX
@article{Khan2023,
  author = {Khan, Aliya A and AbuAlrob, Hajar and M'Hiri, Iman and Ali, Dalal S and Dandurand, Karel and Said, Hosay and Alkassem, Hisham and Hakami, Yasser and Hweija, Ismail and Iqbal, Salman and Romanovschi, Mihai and Mehmood, Shehryar and Zariffeh, Heather and Guyatt, Gordon and Ibrahim, Quazi and Brignardello-Petersen, Romina and Syed, Hamza I},
  title = {Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study},
  journal = {Endocrine},
  year = {2023},
  doi = {10.1007/s12020-022-03230-5}
}
Kostenlos starten →